Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
459 Results for "
PROTAC compound
" in MedChemExpress (MCE) Product Catalog:
Products (459)
459 Results for "PROTAC compound" in MCE Product Catalog:
Cat. No.: HY-153673
CAS No.: 2911615-06-8
Research Areas:
PROTAC IRAK4 degrader-8 (Compound 2) is a PROTAC degrader that targets IRAK4 by recruiting cereblon. PROTAC IRAK4 degrader-8 inhibits IRAK4 kinase activity with an IC50 of 15.5 nM. PROTAC IRAK4 degrader-8 suppresses IL-6 production in immune cells. PROTAC IRAK4 degrader-8 can be used in the research of inflammatory diseases, immune diseases and cancers .
Research Areas:
PROTAC HER3-binding moiety 1 (compound 1b) is a Her3 Ligand for PROTAC .
Cat. No.: HY-178797
CAS No.: 3080678-98-1
Research Areas:
PROTAC LRRK2 Degrader-3 (compound 6) is a PROTAC LRRK2 degrader with a DC50 of 0.17 nM. PROTAC LRRK2 Degrader-3 can be used for research in Parkinson’s disease and inflammation .
Cat. No.: HY-161616
CAS No.: 3010273-13-6
Research Areas:
ATR-IN-30 (Compound 5) is a selective ATR ligand, and can be used for synthesis of ATR PROTACs, such as PROTAC ATR degrader-2 (HY-161615) .
Cat. No.: HY-128527
CAS No.: 2158322-29-1
Research Areas:
PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) .
Cat. No.: HY-160221
CAS No.: 2505495-83-8
Target:
Research Areas:
PROTAC AR Degrader-7 (compound 99) is a PROTAC targeting androgen receptor with an IC50 value of 3 nM .
Cat. No.: HY-107445
CAS No.: 2097512-23-5
Research Areas:
PROTAC BRD9-binding moiety 1 is a compound that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.
Cat. No.: HY-159608
CAS No.: 3035210-39-7
Target:
Research Areas:
PROTAC Cbl-b-IN-1 (compound 64) is a potent Cbl-b PROTAC degrader with a DC50 of less than 30 nM. PROTAC Cbl-b-IN-1 can be used for cancer research .
Cat. No.: HY-155072
CAS No.: 3049086-75-8
PROTAC BTK degraders-5(compound 3e) is a selective BTK PROTAC degrader with a DC50 value of 7.0 nM in JeKo-1 cells. PROTAC BTK degraders-5 has no off-target effect on degrading CRBN neosubstates. PROTAC BTK degraders-5 has anti-proliferation effect on various lymphoma tumor cells and can be used in chronic lymphoid malignancies research .
Cat. No.: HY-130500
CAS No.: 1346502-15-5
Target:
Research Areas:
Br-PEG3-CH2COOH (compound 28) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
Cat. No.: HY-162245
CAS No.: 3024266-69-8
Target:
Research Areas:
PROTAC SMARCA2 degrader-3 is a PROTAC degrader of the SWI/SNF ATPase subunits, SMARCA2. PROTAC SMARCA2 degrader-3 has anticancer effects (WO2023244764A1; Compound 153) .
Cat. No.: HY-170769
CAS No.: 2769753-49-1
Research Areas:
FLT3 Ligand-Linker Conjugate 1 (compound 7) contains the FLT3 ligand and a PROTAC linker, which can recruit the E3 ligase VHL. FLT3 Ligand-Linker Conjugate 1 can be used to synthesize the PROTAC RSS0680 (HY-148062). PROTAC RSS0680 is a bifunctional compound that targets protein degradation of kinases .
Cat. No.: HY-177729
Target:
Research Areas:
PROTAC BRD9 Degrader-9 (Compound 16) is an efficient and selective targeting BRD9 PROTAC degrader. PROTAC BRD9 Degrader-9 does not cause significant cytotoxicity. PROTAC BRD9 Degrader-9 can be used for cancer research
Cat. No.: HY-153820
CAS No.: 2086300-61-8
Target:
Research Areas:
PROTAC BRD4 Degrader-20 (Compound 195) is a PROTAC degrader that targets BRD4 for degradation by recruiting VHL. PROTAC BRD4 Degrader-20 is applicable to the research of diffuse large B-cell lymphoma .
Cat. No.: HY-160264
Target:
Research Areas:
PROTAC ER Degrader-12 (Compound 70) is an estrogen receptor PROTAC degrader (DC50: <10 nM), and inhibits MCF-7 proliferation (DC50: <10 nM). PROTAC ER Degrader-12 has anticancer effect .
Cat. No.: HY-161749
CAS No.: 3049802-45-8
Research Areas:
PROTAC ALK degrader-1 (compound B1) is an ALK degrader based on PROTACs, with the DC50 of 26 nM in H3122 EML4-ALK. PROTAC ALK degrader-1 can be used to synthesis PROTAC ALK degrader-2 (HY-161750) with superior bioavailability .
Cat. No.: HY-168057
CAS No.: 3024971-78-3
PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader for cyclin-dependent kinase 2 (CDK2). PROTAC CDK2 Degrader-1 inhibits the phosphorylation of RB protein in CDK2 dependent cell line OVCAR3 with an IC50 of 100-500 nM .
Cat. No.: HY-128528
Research Areas:
PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
